South Korea · Delayed Price · Currency is KRW Shaperon Company Description
Shaperon Inc., a clinical stage biotech company, develops novel inflammasome inhibitors targeting immune-mediated inflammatory disorders with high unmet medical needs and nanobody therapeutics.
It offers NuGel, a gel type atopic dermatitis drug candidate in Phase 2 clinical trials; and NuSepin, an IV injection form of HY209 in Phase 2 clinical trials for use in the treatment of systemic inflammatory response syndrome.
The company also provides Oral HY209, an oral formulation of HY209 for use in the treatment of neuroinflammatory diseases; and HY209 Analogues for treating chronic inflammation.
In addition, it offers Papiliximab, a bispecific nanobody targeting PD-L1 and CD47, a novel immunotherapy targeting both innate and adaptive immunity; and Saviximab, a single domain neutralizing antibody for SARS-CoV-2, as well as an undisclosed nanobody product candidate for use in oncology.
The company was founded in 2008 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 2008 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 49 |
| CEO | Seung-Yong Seong |
Contact Details
Address: Gangnam Ace Tower G9 Seoul, 06373 South Korea | |
| Phone | 82 2 6083 8315 |
| Website | shaperon.com |
Stock Details
| Ticker Symbol | 378800 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Seung-Yong Seong | Chief Executive Officer |
| Gene Yune | Chief Financial Officer |